IL17A and rheumatoid arthritis: A novel platform was constructed by Wang et al. who introduced a cationic hydrogel loaded with anti-IL-17A nanobodies (Nbs) to synergistically suppress neutrophil-mediated inflammation in RA (Figure 3) [117].